YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy

Rahimi, Rahim; Hosseini, Seyed Younes; Fattahi, Mohammad Reza; Sepehrimanesh, Masood; Safarpour, Ali Reza; Malekhosseini, Seyed Ali; Nejabat, Mahmood; Khodadad, Mahboobeh; Ardebili, Maryam

doi:10.5812/hepatmon.27120v2

Cited by 12 publications

(12 citation statements)

References 39 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…rtM204I + rtL180M was identified in a study by Lok et al (26) Kobayashi et al (27) detected YMDD mutations in HBV asymptomatic carriers who did not receive LAM therapy. Furthermore, the YMDD mutation was detected in patients with chronic hepatitis B that underwent pre-therapy with LAM (28,29), which differs from the previous conclusion that LAM therapy induced YMDD mutations (30). In the present study, no YMDD mutations were detected at baseline and after 6 months of LAM therapy, while two common types of mutations: rtM204V + rtL180M (2 cases) and rtL180M alone (2 cases) were identified after 12 months LAM therapy, and no rtM204I was found.…”

Section: Discussioncontrasting

confidence: 53%

Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy

Yuan

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the correlation between feature and genotype with regard to the tyrosine-methionine-aspartate-aspartate (YMDD) mutation in chronic hepatitis B patients after lamivudine (LAM) therapy. A total of 30 patients with chronic hepatitis B were recruited, who underwent one year of LAM therapy. The patients' alanine aminotransferase (ALT) level and hepatitis B envelope antigen (HBeAg) seroconversion were evaluated, hepatitis B virus (HBV) DNA was genotyped using a new genotyping method and YMDD mutations were analyzed prior to treatment and at 6 and 12 months after LAM treatment. Furthermore, the secondary protein structure of the HBV DNA polymerase gene (P gene) was analyzed. Following treatment, the results suggested that LAM therapy improved ALT normalization. There was no correlation between clinical effects and ALT level before treatment. After 12 months treatment, the rate of HBeAg loss increased and the rate of HBeAg seroconversion decreased linearly with the rise of baseline ALT level. While ALT normalization and HBeAg seroconversion were highest in patients with HBV genotype B, HBeAg loss and HBVDNA loss were highest in those with genotype C. The effect was predominant in genotype D. No YMDD mutations were identified prior to 6 months of LAM therapy. The rate of YMDD mutations after 12 months LAM therapy was 12.12%. Two patients with rtM204V + rtL180M belonged to genotype C and another patient with rtL180M alone belonged to genotype D. The turn of secondary protein structure of P gene changed to β sheet when a rtM204V mutation occurred, and no change of secondary protein structure was associated with the rtL180M mutation. Thus, the present results indicate that one year of LAM therapy is able to improve ALT normalization. Long-term LAM therapy may induce YMDD mutation and drug resistance.

show abstract

Section: Discussioncontrasting

confidence: 53%

Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy

Yuan

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…The first was already found in individuals with simultaneous positivity for HBsAg and anti-HBs [Li et al, 2009;Pu et al, 2015]. Furthermore, Y134N was also identified in HBV carriers with resistance mutations to nucleoside and nucleotide analogs in liver transplant recipients with occult hepatitis B [Rahimi et al, 2015], and in individuals with occult Hepatitis B and hepatocellular carcinoma [Pollicino et al, 2007]. Therefore, this is not a specific mutation of atypical profile of concomitant HBsAg and anti-HBs positivity; however, it may have probably its role.…”

Section: Discussionmentioning

confidence: 96%

Mutation in the S gene a determinant of the hepatitis B virus associated with concomitant HBsAg and anti‐HBs in a population in Northeastern Brazil

Albuquerque

Sousa

Santos

et al. 2016

Journal of Medical Virology

View full text Add to dashboard Cite

Mutations in the a determinant of S gene may develop co-existence of hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) in the serum of infected hepatitis B virus (HBV) individuals. Mutations in this region may change the antigenicity of HBsAg, which in turn, lead to escape of neutralizing action of anti-HBs antibodies. This study identified individuals with concomitant HBsAg and anti-HBs serological markers in individuals of Maranhão, Northeastern Brazil. Samples from a population-based study were evaluated for HBsAg, anti-HBs, and anti-HBc, and those that tested positive for simultaneous HBsAg and anti-HBs were submitted to HBV DNA quantification and S gene characterization by Sanger sequencing. Mutations were investigated in the a determinant located in major hydrophilic region (MHR) of the S gene. Among 3,984 samples analyzed, 92 (2.3%) were positive for HBsAg and three had the atypical HBsAg and anti-HBs-positive profile (3.26%). The frequency of HBsAg and anti-HBs co-existence was similar to previous studies. Only one individual harbored mutation in the S gene a determinant associated with this profile. Little is known about this phenomenon; however, studies as ours may contribute for future enlightenment of this important issue. J. Med. Virol. 89:458-462, 2017. © 2016 Wiley Periodicals, Inc.

show abstract

“…The hepatitis B virus (HBV) is a viral agent whose target tissue is liver and can cause both acute and chronic illnesses [1]. According to the 2016 World Health Organization (WHO) statistics, 240 million people who are positive for at least 6 months of HBsAg are reported as HBV positive individuals [2].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive investigation of the prevalence and risk factors of viral hepatitis B and C in PERSIAN Guilan Cohort Study

Joukar

Naghipour

Hassanipour

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Background Hepatitis B (HBV) and C (HCV) viruses are two serious infectious diseases with high global health impact. The aim of this study was to evaluate the prevalence of HBV and HCV in the Prospective Epidemiological Research Studies of the Iranian Adults (PERSIAN) Guilan Cohort Study through immunological and molecular methods.Methods The blood samples were obtained from 10520 enrolled participant. Complete biochemical and hematological assessments plus urine analysis were done. The presence of HBsAg, anti-HBs, anti-HBc and anti-HCV antibodies for all participants and HBeAg and anti-HBe antibody for HBV positive patients were evaluated. HBV genomic DNA and HCV genomic RNA were extracted from positive serum samples. Real time PCR assay was done to quantify HBV and HCV genomes. HCV genotyping was also performed.Results Most of our participants were female (53.5%), rural (56.1%), married (97.2%) with primary education (72.1%) without smoking (75.2%) or alcohol consumption (85.3%). The HBV and HCV prevalence was 0.24% (95% CI, 0.16% to 0.35%) and 0.11% (95% CI, 0.06% to 0.19%), respectively. Rural participants were significantly more HBV positive than urban peoples (P=0.045) while male individuals were significantly more HCV positive than female participants (P=0.013).Conclusion Our detected HBV and HCV prevalence were lower than other cities/provinces of Iran, which may be due to the lifestyle or other unknown reasons.

show abstract

YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy

Cited by 12 publications

References 39 publications

Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy

Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy

Mutation in the S gene a determinant of the hepatitis B virus associated with concomitant HBsAg and anti‐HBs in a population in Northeastern Brazil

Comprehensive investigation of the prevalence and risk factors of viral hepatitis B and C in PERSIAN Guilan Cohort Study

Contact Info

Product

Resources

About